

Federica Vianello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1341823/publications.pdf>

Version: 2024-02-01

30
papers

2,494
citations

331538

21
h-index

454834

30
g-index

30
all docs

30
docs citations

30
times ranked

2894
citing authors

#	ARTICLE	IF	CITATIONS
1	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. <i>Frontiers in Endocrinology</i> , 2022, 13, 834075.	1.5	5
2	The role of the size in thyroid cancer risk stratification. <i>Scientific Reports</i> , 2021, 11, 7303.	1.6	2
3	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3228-3238.	1.8	36
4	<i>BRAF</i> V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. <i>European Journal of Cancer</i> , 2020, 124, 161-169.	1.3	41
5	Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 7845-7855.	0.9	6
6	Differentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario. <i>Frontiers in Endocrinology</i> , 2019, 10, 552.	1.5	33
7	Prognostic significance of TERT promoter and <i>BRAF</i> mutations in TIR-4 and TIR-5 thyroid cytology. <i>European Journal of Endocrinology</i> , 2019, 181, 1-11.	1.9	39
8	<i>BRAF</i> V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. <i>Journal of the National Cancer Institute</i> , 2018, 110, 362-370.	3.0	60
9	The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes. <i>Thyroid</i> , 2018, 28, 96-103.	2.4	40
10	Patient Age-Associated Mortality Risk Is Differentiated by <i>BRAF</i> V600E Status in Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 438-445.	0.8	102
11	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2787-2795.	0.8	58
12	EF24 (a Curcumin Analog) and ZSTK474 Emphasize the Effect of Cabozantinib in Medullary Thyroid Cancer. <i>Endocrinology</i> , 2018, 159, 2348-2360.	1.4	21
13	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3241-3250.	1.8	80
14	MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical pathological features and outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 651-658.	1.4	25
15	Frequency and Significance of Ras, Tert Promoter, and <i>Braf</i> Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit. <i>Frontiers in Endocrinology</i> , 2017, 8, 273.	1.5	31
16	Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-9.	0.6	23
17	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 264-274.	1.8	179
18	<i>BRAF</i> analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1531-1539.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 42-50.	0.8	448
20	A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. <i>Oncotarget</i> , 2015, 6, 32104-32114.	0.8	23
21	High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdrawal. <i>Thyroid</i> , 2014, 24, 480-487.	2.4	28
22	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1493.	3.8	775
23	Comparison of the diagnostic accuracy of combined elastosonography and <i>BRAF</i> analysis vs cytology and ultrasonography for thyroid nodule suspected of malignancy. <i>Clinical Endocrinology</i> , 2012, 77, 608-614.	1.2	10
24	MicroRNA Profiles in Familial and Sporadic Medullary Thyroid Carcinoma: Preliminary Relationships with RET Status and Outcome. <i>Thyroid</i> , 2012, 22, 890-896.	2.4	116
25	<i>BRAF</i> ^{K601E} Mutation in a Patient with a Follicular Thyroid Carcinoma. <i>Thyroid</i> , 2011, 21, 1393-1396.	2.4	48
26	Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. <i>European Journal of Endocrinology</i> , 2011, 164, 971-976.	1.9	86
27	<i>BRAF</i> analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 325-329.	1.4	48
28	Follicular Thyroid Carcinoma with Metastases to the Pituitary Causing Pituitary Insufficiency. <i>Thyroid</i> , 2011, 21, 921-925.	2.4	16
29	BRAF in primary and recurrent papillary thyroid cancers: the relationship with 131I and 2-[18F]fluoro-2-deoxy-d-glucose uptake ability. <i>European Journal of Endocrinology</i> , 2010, 163, 659-663.	1.9	55
30	Primary Mediastinal Large B-Cell Lymphoma: Results of Intensive Chemotherapy Regimens (MACOP-B/VACOP-B) Plus Involved Field Radiotherapy on 53 Patients. A Single Institution Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 823-829.	0.4	48